Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Nephrology
•
General Infectious Disease
How do you approach the use of Paxlovid in patients with COVID-19 and CKD Stage 4?
CKD Stage 4: eGFR between 15 and 29 mL/min/1.73 m²
Nieves MC, et al., PMID 40204015
Related Questions
Do you routinely continue dual antibiotic coverage or de-escalate to monotherapy based on peritoneal fluid culture sensitivities in patients with relapsing pseudomonas aeruginosa peritoneal dialysis peritonitis after peritoneal catheter removal?
Has your institution and/or antimicrobial stewardship program incorporated a selective antibiotic approach to treatment of left-sided uncomplicated diverticulitis in immunocompetent patients?
How often do you see bony erosions in patients with Lyme arthritis?
Do you approach suppressive antibiotic therapy differently for patients with cardiac implant- able electronic devices infections compared to patients with LVAD related infections?
Do you avoid Daptomycin use when there is evidence of septic pulmonary emboli?
Do you treat complicated pneumonia with a drained empyema longer if Streptococcus anginosus is cultured, either in isolation or with other organisms, compared to cases in which it is not?
How have the results of the BALANCE trial, which demonstrated the noninferiority of 7 days of antibiotics compared to 14 days for non-S. aureus bloodstream infections, influenced your practice?
Do you routinely check cefepime levels in patient's with suspected cefepime-induced neurotoxicity?
How do you approach perioperative antimicrobial prophylaxis in patients undergoing reconstructive surgery with myocutaneous flaps whom have recently been treated for active infection?
Do you recommend low or intermediate dosing of TMP-SMX over high dosing for the initial treatment of non-disseminated pulmonary nocardiosis?
